(Q42723815)
Statements
1 reference
Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer (English)
1 reference
Keith T Flaherty
1 reference
Keith D Wilner
1 reference
Patricia M Lorusso
1 reference
Angela Demichele
1 reference
Vandana G Abramson
1 reference
Rachel Courtney
1 reference
Sophia S Randolph
1 reference
M Naveed Shaik
1 reference
Peter J O'Dwyer
1 reference
Gary K Schwartz
1 reference
16 November 2011
1 reference
1 reference
Identifiers
1 reference